SpaceX Starship V3 Test Flight Successfully Launches After Delay Abercrombie Fitch Shares Surge on Strong Earnings Marking 14th Consecutive Quarter of Sales Growth Microchip Technology Receives Price Target Upgrades Amid Signs of Semiconductor Recovery Water Crisis at Americas Largest Oil Export Hub Threatens Energy Operations Jardines Acquires Australian Radiology Leader in 24 Billion Deal Morgan Stanley Adjusts Palo Alto Networks Price Target Amid Shifting Cybersecurity Demand BKYI Q1 2026 Earnings EPS Surprise Beats Estimates by 75 WKHS Q1 2026 Earnings Deeper Losses on Zero Revenue Highlight EV Startups Cash Challenges TRIN Q1 2026 Earnings EPS Beats Estimates by 116 Shares Decline Slightly PLAYSTUDIOS Inc MYPS Q1 2026 Earnings EPS Miss Signals Headwinds for Mobile Gaming Developer WEC Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response UTSI Q4 2019 Earnings Significant EPS Miss Sends Stock Down Definium Therapeutics DFTX Slips 066 as Shares Test Key Support Zone Sable Offshore Corp SOC Edges Lower Amid Resistance Test Stock Holds Above Key Support at 1375 Ring Energy Inc REI Edges Higher Amid Energy Sector Fluctuations Cadrenal Therapeutics CVKD Holds Steady Consolidating Between Support and Resistance abrdn Income Credit Strategies Fund ACP Edges Higher Amid Steady Trading Geopolitical Tensions Rise as Putin Vows Retaliation After Alleged Ukrainian Strike on Military Target LIXT Q4 2024 Earnings Biotech Reports Net Loss Stock Declines BGX Edges Higher Blackstone LongShort Credit Income Fund Nears Key Support HLX Q1 2026 Earnings Earnings Miss Weighs on Shares as Helix Energy Posts WiderThanExpected Loss Global Ship Lease Inc New GSL Q4 2025 Earnings EPS Miss Weighs on Sentiment Amid Operational Stability Cramer Offers Cautious Market Outlook With Selective Stock Picks Workday Shares Surge 14 as AI Strength Drives Up Margin Guidance MCHX Q1 2026 Earnings EPS Misses Estimates as Stock Declines Microbot Medical Inc MBOT Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Market Reaction XORTX Therapeutics Q1 2024 Earnings Steep EPS Miss Highlights PreRevenue Biotech Hurdles